Edition:
United States

Alimera Sciences Inc (ALIM.O)

ALIM.O on Consolidated Issue listed on NASDAQ Global Market

1.30USD
12 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.30
Open
$1.29
Day's High
$1.32
Day's Low
$1.28
Volume
50,316
Avg. Vol
169,510
52-wk High
$1.72
52-wk Low
$1.06

Latest Key Developments (Source: Significant Developments)

Alimera Sciences Inc reports qtrly loss per share ‍$0.08​
Wednesday, 1 Nov 2017 05:36pm EDT 

Nov 1 (Reuters) - Alimera Sciences Inc :Alimera Sciences Inc reports third quarter 2017 financial results.Q3 revenue rose 18 percent to $9.8 million.Alimera Sciences Inc qtrly loss per share ‍$0.08​.  Full Article

Alimera Sciences ‍announces Iluvien now available in Ireland​
Tuesday, 12 Sep 2017 04:01pm EDT 

Sept 12 (Reuters) - Alimera Sciences Inc :Alimera Sciences Inc - ‍Announces Iluvien now available in Ireland​.  Full Article

Alimera Sciences signs agreement for distribution of Iluvien in France
Tuesday, 29 Aug 2017 04:05pm EDT 

Aug 29 (Reuters) - Alimera Sciences Inc :Alimera Sciences signs agreement for exclusive distributor of Iluvien in France.Alimera Sciences Inc - ‍Under agreement, Horus will serve as Alimera's exclusive distributor in France for Iluvien​.Alimera Sciences - ‍Alimera Sciences Limited, Co's European subsidiary based in United Kingdom, has signed a distribution agreement with Horus Pharma S.A.S.​.  Full Article

Alimera Sciences Q2 ‍net loss per share $0.04​
Wednesday, 2 Aug 2017 05:48pm EDT 

Aug 2 (Reuters) - Alimera Sciences Inc :Alimera Sciences reports second quarter 2017 financial results.Q2 revenue rose 8 percent to $10.4 million.Alimera Sciences Inc - qtrly ‍net loss per share basic and diluted $0.04​.Q2 earnings per share view $-0.05, revenue view $10.3 million -- Thomson Reuters I/B/E/S.  Full Article

pSivida- in connection with new collaboration agreement, Alimera forgave $10 mln of co's share of losses associated with commercialization of ILUVIEN
Monday, 10 Jul 2017 05:40pm EDT 

July 10 (Reuters) - pSivida Corp : :pSivida - in connection with new collaboration agreement, alimera forgave $10 million of co's share of losses associated with commercialization of ILUVIEN.pSivida Corp - Alimera will forgive an additional $5 million of remaining $15 million of previous losses upon approval of iluvien.pSivida - in connection with new collaboration agreement, alimera has right to recover $15 million of such previous losses as partial offset to future royalty payments.pSivida Corp - if amounts recoverable by Alimera are less than $5 million at that time, Alimera will pay company difference in cash.pSivida Corp - has right to recover $15 million of previous losses as a partial offset to future royalty payments.  Full Article

ALIMERA SCIENCES REPORTS Q1 LOSS PER SHARE $0.10
Monday, 8 May 2017 04:58pm EDT 

May 8 (Reuters) - Alimera Sciences Inc :ALIMERA SCIENCES REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS.Q1 REVENUE ROSE 14 PERCENT TO $6.6 MILLION.QTRLY LOSS PER SHARE $0.10.  Full Article

Alimera Sciences signs agreement for exclusive distributor of Iluvien in Spain
Monday, 13 Mar 2017 07:30am EDT 

Alimera Sciences Inc : Alimera Sciences signs agreement for exclusive distributor of Iluvien in Spain . Says under terms of this agreement, Brill Pharma will handle promotion, marketing and commercial activities in spain for Iluvien .Brill will negotiate with Spanish Ministry of Health on appropriate confidential net price for reimbursement of Iluvien.  Full Article

Alimera Sciences Q4 adjusted non-gaap loss per share $0.10
Wednesday, 1 Mar 2017 04:00pm EST 

Alimera Sciences Inc : Alimera sciences reports record fourth quarter and full year 2016 financial results . Q4 adjusted non-gaap loss per share $0.10 . Q4 gaap loss per share $0.09 . Q4 revenue rose 84 percent to $10.7 million .Expects its distributors in italy and middle east to further availability of iluvien in 2017.  Full Article

Alimera Sciences and Knight Therapeutics file new drug submission for iluvien in Canada
Wednesday, 22 Feb 2017 08:00am EST 

Alimera Sciences Inc : Alimera Sciences and Knight Therapeutics announce filing of new drug submission for iluvien in Canada .Alimera Sciences Inc - Knight's new drug submission (NDS) for iluvien has been accepted for review by Health Canada.  Full Article

Stonepine Capital LP reports 5.4 pct passive stake in Alimera Sciences
Thursday, 17 Nov 2016 02:42pm EST 

Alimera Sciences Inc :Stonepine Capital LP reports 5.4 percent passive stake in Alimera Sciences Inc as of Nov 7 - sec filing.  Full Article